ACS Nano· 2026Q1
Scavenger Receptor Class B Type 1 Mediated Transport Enables Delivery Across Capillarized Liver Sinusoids in Metabolic Dysfunction-Associated Steatohepatitis
- 0citations
- Q1SCImago
- 2026year
Short summary
A novel liposomal nanocarrier, SV@SRB-Lip, engineered to exploit scavenger receptor class B type 1 (SR-B1)-mediated transport, successfully delivered simvastatin across capillarized liver sinusoids and into fibrotic regions in MASH mice, suppressing fibrosis.
AI-generated from the title and abstract; the full text is not read.
Key points
- A novel nanocarrier, SV@SRB-Lip, was engineered to exploit SR-B1-mediated transport across capillarized liver sinusoids.
- SV@SRB-Lip successfully delivered simvastatin to fibrotic regions in MASH mice, enhancing hepatic accumulation.
- The nanocarrier suppressed hepatic stellate cell activation and collagen deposition, improving MASH-associated fibrosis.
AI-generated from the title and abstract; the full text is not read.
Abstract
Abstract Liver fibrosis in metabolic dysfunction associated steatohepatitis (MASH) lacks effective therapies, in part because therapeutic agents poorly penetrate the capillarized sinusoidal endothelium. As fibrosis progresses, liver sinusoidal endothelial cells (LSECs) become defenestrated and restrict trans-sinusoidal exchange, thereby limiting drug access to hepatic stellate cells (HSCs) within the perisinusoidal space. Here, we developed a lipoprotein mimetic liposomal nanocarrier, SV@SRB-Lip, to exploit scavenger receptor class B type 1 (SR-B1)-associated transendothelial transport across capillarized LSECs and enhance downstream delivery toward HSC-associated fibrotic regions. SV@SRB-Lip was engineered as a simvastatin loaded liposomal platform incorporating an ApoA-I-mimetic SRB peptide, an MMP-responsive linker, and a vitamin A modified lipid moiety. SV@SRB-Lip promoted transport across the LSEC monolayer in vitro, and this effect was reduced by SR-B1 silencing, supporting the involvement of SR-B1-associated endothelial transport. In MASH mice, SV@SRB-Lip enhanced hepatic delivery and distributed toward HSC associated fibrotic regions. The MMP-responsive design increased the relative accessibility of vitamin A within the fibrotic microenvironment, supporting downstream HSC associated uptake. As a result, SV@SRB-Lip increased hepatic simvastatin accumulation, suppressed HSC activation and collagen deposition, and improved MASH associated fibrosis. These findings suggest that SR-B1-associated endothelial transport can be harnessed to overcome the capillarized sinusoidal barrier and improve antifibrotic nanomedicine delivery in MASH.
The authors' abstract, as published at the source. ACS Nano, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Hepatology
HepatologyMedicine